[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604175":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":11,"centralContacts":19,"locations":25,"responsibleParty":51,"collaborators":10,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":10,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":10,"enrollmentInfo":62,"targetDuration":10,"studyType":65,"phases":10,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Ausper Biopharma Co., Ltd.","INDUSTRY",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"Participants who have previously participated in AHB-137 clinical trials",null,[12,16],{"name":13,"affiliation":14,"role":15},"Jinlin Hou","Nanfang Hospital, Southern Medical University","PRINCIPAL_INVESTIGATOR",{"name":17,"affiliation":18,"role":15},"Junqi Niu","The First Hospital of Jilin University",[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Lu","CONTACT","0571-86959519","clinicaltrial@ausperbio.com",[26,41],{"facility":27,"status":28,"city":29,"state":30,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"AusperBio Investigational Site","RECRUITING","Guangzhou","Guangdong","China","CN",{"type":34,"coordinates":35},"Point",[36,37],113.25,23.11667,{"lat":37,"lon":36},[40],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"facility":27,"status":28,"city":42,"state":43,"zip":10,"country":31,"countryCode":32,"cosmosGeoPoint":44,"geoPoint":48,"contacts":49},"Changchun","Jilin",{"type":34,"coordinates":45},[46,47],125.32278,43.88,{"lat":47,"lon":46},[50],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},{"type":52,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100604175","long-term-follow-up-study-to-evaluate-participants-with-chronic-hepatitis-b-chb-previously-treated-with-ahb-137-injection-100604175",false,"NCT07146100","Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection","Prospective, Open-label, Multicenter Long-term Follow-up Study to Evaluate the Durability of Virologic Response in Participants With Chronic Hepatitis B Previously Treated With AHB-137 Injection","Inclusion Criteria:\n\n* Capable of giving informed consent.\n* Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study.\n\nExclusion Criteria:\n\n* Participants who have\u002For are currently participating in another interventional clinical study since completing their treatment with AHB-137.\n* Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.","ALL","18 Years",{"count":63,"type":64},200,"ESTIMATED","OBSERVATIONAL","This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.",[68],"Chronic Hepatitis B",[70],"Hepatitis B, Chronic","2026-05-01",{"date":73,"type":74},"2026-05-04","ACTUAL",{"date":76,"type":74},"2025-08-28",{"date":78,"type":64},"2030-01-01",{"name":5,"class":6},2]